Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
NHC vs CCRN vs HCSG vs HCA vs ENSG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
NHC vs CCRN vs HCSG vs HCA vs ENSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $2.66B | $423M | $1.60B | $95.95B | $10.18B |
| Revenue (TTM) | $1.50B | $761M | $1.84B | $75.60B | $5.27B |
| Net Income (TTM) | $101M | $-99M | $59M | $6.78B | $363M |
| Gross Margin | 38.5% | 18.2% | 13.3% | 41.5% | 15.2% |
| Operating Margin | 8.1% | -0.9% | 3.0% | 15.8% | 8.5% |
| Forward P/E | 21.5x | 133.8x | 20.8x | 14.2x | 23.2x |
| Total Debt | $87M | $2M | $25M | $50.20B | $4.15B |
| Cash & Equiv. | — | $109M | $161M | $1.04B | $504M |
NHC vs CCRN vs HCSG vs HCA vs ENSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| National HealthCare… (NHC) | 100 | 255.6 | +155.6% |
| Cross Country Healt… (CCRN) | 100 | 215.7 | +115.7% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
| HCA Healthcare, Inc. (HCA) | 100 | 401.5 | +301.5% |
| The Ensign Group, I… (ENSG) | 100 | 398.7 | +298.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NHC vs CCRN vs HCSG vs HCA vs ENSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NHC is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 12 yrs, beta 0.60, yield 1.4%
- 1.4% yield, 12-year raise streak, vs HCA's 0.7%, (2 stocks pay no dividend)
- +81.9% vs CCRN's -5.4%
CCRN is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
Among these 5 stocks, HCSG doesn't own a clear edge in any measured category.
HCA carries the broadest edge in this set and is the clearest fit for valuation efficiency and defensive.
- PEG 0.67 vs ENSG's 1.68
- Beta 0.29, yield 0.7%, current ratio 0.83x
- Lower P/E (14.2x vs 23.2x), PEG 0.67 vs 1.68
- 9.0% margin vs CCRN's -13.0%
ENSG ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- 7.5% 10Y total return vs HCA's 450.5%
- 18.7% revenue growth vs CCRN's -21.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (14.2x vs 23.2x), PEG 0.67 vs 1.68 | |
| Quality / Margins | 9.0% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.29 vs HCSG's 1.12 | |
| Dividends | 1.4% yield, 12-year raise streak, vs HCA's 0.7%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +81.9% vs CCRN's -5.4% | |
| Efficiency (ROA) | 11.3% ROA vs CCRN's -19.8%, ROIC 19.9% vs -0.9% |
NHC vs CCRN vs HCSG vs HCA vs ENSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NHC vs CCRN vs HCSG vs HCA vs ENSG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HCA leads in 2 of 6 categories
CCRN leads 1 • NHC leads 1 • HCSG leads 0 • ENSG leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HCA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 99.4x CCRN's $761M. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, ENSG holds the edge at +18.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $761M | $1.8B | $75.6B | $5.3B |
| EBITDAEarnings before interest/tax | $166M | $9M | $72M | $15.5B | $558M |
| Net IncomeAfter-tax profit | $101M | -$99M | $59M | $6.8B | $363M |
| Free Cash FlowCash after capex | $147M | $41M | $139M | $7.7B | $406M |
| Gross MarginGross profit ÷ Revenue | +38.5% | +18.2% | +13.3% | +41.5% | +15.2% |
| Operating MarginEBIT ÷ Revenue | +8.1% | -0.9% | +3.0% | +15.8% | +8.5% |
| Net MarginNet income ÷ Revenue | +6.7% | -13.0% | +3.2% | +9.0% | +6.9% |
| FCF MarginFCF ÷ Revenue | +9.8% | +5.4% | +7.6% | +10.2% | +7.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +12.5% | -100.0% | +6.6% | +6.7% | +18.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -8.4% | -6.0% | +175.0% | +44.6% | +21.9% |
Valuation Metrics
CCRN leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 15.1x trailing earnings, HCA trades at a 49% valuation discount to ENSG's 29.8x P/E. Adjusting for growth (PEG ratio), HCA offers better value at 0.72x vs ENSG's 2.16x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.7B | $423M | $1.6B | $95.9B | $10.2B |
| Enterprise ValueMkt cap + debt − cash | $2.7B | $317M | $1.5B | $145.1B | $13.8B |
| Trailing P/EPrice ÷ TTM EPS | 22.35x | -4.47x | 27.54x | 15.12x | 29.85x |
| Forward P/EPrice ÷ next-FY EPS est. | 21.51x | 133.84x | 20.83x | 14.19x | 23.19x |
| PEG RatioP/E ÷ EPS growth rate | 0.97x | — | — | 0.72x | 2.16x |
| EV / EBITDAEnterprise value multiple | 15.85x | 23.75x | 22.38x | 9.37x | 25.71x |
| Price / SalesMarket cap ÷ Revenue | 1.81x | 0.40x | 0.87x | 1.27x | 2.01x |
| Price / BookPrice ÷ Book value/share | 2.50x | 1.31x | 3.19x | — | 4.59x |
| Price / FCFMarket cap ÷ FCF | 17.89x | 10.55x | 11.49x | 12.47x | 27.46x |
Profitability & Efficiency
HCA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ENSG delivers a 16.6% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), HCSG scores 7/9 vs NHC's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.6% | -27.1% | +11.8% | — | +16.6% |
| ROA (TTM)Return on assets | +6.4% | -19.8% | +7.3% | +11.3% | +6.8% |
| ROICReturn on invested capital | +8.4% | -0.9% | +9.0% | +19.9% | +7.0% |
| ROCEReturn on capital employed | — | -0.8% | +7.7% | +27.0% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 7 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.08x | 0.01x | 0.05x | — | 1.86x |
| Net DebtTotal debt minus cash | $87M | -$106M | -$136M | $49.2B | $3.7B |
| Cash & Equiv.Liquid assets | — | $109M | $161M | $1.0B | $504M |
| Total DebtShort + long-term debt | $87M | $2M | $25M | $50.2B | $4.2B |
| Interest CoverageEBIT ÷ Interest expense | 24.41x | -1.39x | 33.02x | 5.37x | 88.33x |
Total Returns (Dividends Reinvested)
NHC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NHC five years ago would be worth $26,213 today (with dividends reinvested), compared to $7,746 for CCRN. Over the past 12 months, NHC leads with a +81.9% total return vs CCRN's -5.4%. The 3-year compound annual growth rate (CAGR) favors NHC at 46.5% vs CCRN's -17.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +31.9% | +62.4% | +28.6% | -8.6% | +0.3% |
| 1-Year ReturnPast 12 months | +81.9% | -5.4% | +55.8% | +19.7% | +27.5% |
| 3-Year ReturnCumulative with dividends | +214.6% | -44.3% | +48.6% | +57.4% | +88.9% |
| 5-Year ReturnCumulative with dividends | +162.1% | -22.5% | -21.1% | +109.7% | +103.2% |
| 10-Year ReturnCumulative with dividends | +198.2% | -10.5% | -26.8% | +450.5% | +752.0% |
| CAGR (3Y)Annualised 3-year return | +46.5% | -17.7% | +14.1% | +16.3% | +23.6% |
Risk & Volatility
Evenly matched — NHC and HCA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than HCSG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NHC currently trades 93.1% from its 52-week high vs HCA's 77.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.60x | 0.78x | 1.12x | 0.29x | 0.42x |
| 52-Week HighHighest price in past year | $184.08 | $14.99 | $24.39 | $556.52 | $218.00 |
| 52-Week LowLowest price in past year | $93.54 | $7.43 | $12.66 | $330.00 | $133.81 |
| % of 52W HighCurrent price vs 52-week peak | +93.1% | +87.3% | +91.5% | +77.1% | +80.0% |
| RSI (14)Momentum oscillator 0–100 | 51.2 | 53.1 | 61.8 | 30.8 | 23.3 |
| Avg Volume (50D)Average daily shares traded | 117K | 552K | 676K | 1000K | 358K |
Analyst Outlook
Evenly matched — NHC and HCSG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CCRN as "Hold", HCSG as "Hold", HCA as "Buy", ENSG as "Buy". Consensus price targets imply 27.6% upside for ENSG (target: $222) vs -18.9% for CCRN (target: $11). For income investors, NHC offers the higher dividend yield at 1.44% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $10.61 | $24.50 | $527.45 | $222.33 |
| # AnalystsCovering analysts | — | 14 | 15 | 46 | 13 |
| Dividend YieldAnnual dividend ÷ price | +1.4% | — | — | +0.7% | +0.1% |
| Dividend StreakConsecutive years of raises | 12 | 1 | 20 | 5 | 12 |
| Dividend / ShareAnnual DPS | $2.47 | — | — | $2.94 | $0.24 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +1.6% | +3.9% | +10.5% | +0.2% |
HCA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CCRN leads in 1 (Valuation Metrics). 2 tied.
NHC vs CCRN vs HCSG vs HCA vs ENSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NHC or CCRN or HCSG or HCA or ENSG a better buy right now?
For growth investors, The Ensign Group, Inc.
(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). HCA Healthcare, Inc. (HCA) offers the better valuation at 15. 1x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate HCA Healthcare, Inc. (HCA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NHC or CCRN or HCSG or HCA or ENSG?
On trailing P/E, HCA Healthcare, Inc.
(HCA) is the cheapest at 15. 1x versus The Ensign Group, Inc. at 29. 8x. On forward P/E, HCA Healthcare, Inc. is actually cheaper at 14. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: HCA Healthcare, Inc. wins at 0. 67x versus The Ensign Group, Inc. 's 1. 68x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NHC or CCRN or HCSG or HCA or ENSG?
Over the past 5 years, National HealthCare Corporation (NHC) delivered a total return of +162.
1%, compared to -22. 5% for Cross Country Healthcare, Inc. (CCRN). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NHC or CCRN or HCSG or HCA or ENSG?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Healthcare Services Group, Inc. 's 1. 12β — meaning HCSG is approximately 292% more volatile than HCA relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NHC or CCRN or HCSG or HCA or ENSG?
By revenue growth (latest reported year), The Ensign Group, Inc.
(ENSG) is pulling ahead at 18. 7% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NHC or CCRN or HCSG or HCA or ENSG?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCA leads at 15. 8% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — HCA leads at 41. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NHC or CCRN or HCSG or HCA or ENSG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, HCA Healthcare, Inc. (HCA) is the more undervalued stock at a PEG of 0. 67x versus The Ensign Group, Inc. 's 1. 68x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, HCA Healthcare, Inc. (HCA) trades at 14. 2x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 119. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ENSG: 27. 6% to $222. 33.
08Which pays a better dividend — NHC or CCRN or HCSG or HCA or ENSG?
In this comparison, NHC (1.
4% yield), HCA (0. 7% yield), ENSG (0. 1% yield) pay a dividend. CCRN, HCSG do not pay a meaningful dividend and should not be held primarily for income.
09Is NHC or CCRN or HCSG or HCA or ENSG better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, HCSG: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NHC and CCRN and HCSG and HCA and ENSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NHC is a small-cap quality compounder stock; CCRN is a small-cap quality compounder stock; HCSG is a small-cap quality compounder stock; HCA is a mid-cap deep-value stock; ENSG is a mid-cap high-growth stock. NHC, HCA pay a dividend while CCRN, HCSG, ENSG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.